Health · 2 views
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development.
Source NPR AI Summary Updated 1h 27m ago
Health 
Story intelligence Beta
Freshness Fresh Updated 1h 27m ago
Confidence Limited Single-outlet story
Coverage Single outlet
Views 2 Community interest
Read time 1 min ~26 words
AI Summary
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
Read full article on NPRAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are used SUPPORT HAPPENINGNOW · Independent AI News Intelligence
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNowMore from Health
Continue reading recent Health coverage
- Study finds many Colorado jails still lack public opioid treatment policies despite state mandateContinue reading
- Everyone's talking about hormone therapy for menopause. Should I be on it?Continue reading
- FLT3 inhibitors trigger ferroptosis, exposing new weakness in acute myeloid leukemiaContinue reading